Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Februar 2023

Genmab — Februar 2023

Planlagt Fastgjort Låst Flyttet Genmab
713 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • P Offline
    P Offline
    Pensionisten
    wrote on sidst redigeret af
    #37

    Det er imponerende, som der bliver beskrevet, hvad man har gjort. Men yderst sjældent kommentarer på, hvad man agter at gøre. Mon ikke en del er ønsketænkning bagud 😉

    1 Reply Last reply
    0
    • D Offline
      D Offline
      deleted-user
      wrote on sidst redigeret af
      #38

      Hehe. Havde påtænkt at købe Genmab og det skete her til middag 🙂

      1 Reply Last reply
      0
      • D Offline
        D Offline
        deleted-user
        wrote on sidst redigeret af
        #39

        Det kan godt være, at jeg køber flere i morgen eller måske næste uge. Det må tiden vise

        1 Reply Last reply
        0
        • P Offline
          P Offline
          Pensionisten
          wrote on sidst redigeret af
          #40

          😄

          1 Reply Last reply
          0
          • P Offline
            P Offline
            ProinvestorNEWS
            wrote on sidst redigeret af
            #41

            Hvad er en Rasmus Modsat-investering, hvad betyder skuffende tysk vækst, bliver Bavarian Nordics covid-19 muligheder ringere? Det bliver vendt af Hansen & Larsen i ugens podcast, som selvfølgelig også kommer ind på nyt regnskab fra Novo Nordisk, som der stadig ikke er nogen over eller ved siden af. https://www.proinvestor.com/boards/109987

            1 Reply Last reply
            0
            • Helge_LarsenPI-redaktørH Offline
              Helge_LarsenPI-redaktørH Offline
              Helge_LarsenPI-redaktør
              wrote on sidst redigeret af
              #42

              Godmorgen. 🙂

              1 Reply Last reply
              0
              • S Offline
                S Offline
                Stroka
                wrote on sidst redigeret af
                #43

                God morgen 🙂

                1 Reply Last reply
                0
                • B Offline
                  B Offline
                  bibob
                  wrote on sidst redigeret af
                  #44

                  God morgen. 🙂

                  1 Reply Last reply
                  0
                  • B Offline
                    B Offline
                    bibob
                    wrote on sidst redigeret af
                    #45

                    OncLive. D- Rd. Pollux. https://www.onclive.com/view/daratumumab-lenalidomide-dexamethasone-improves-os-in-relapsed-refractory-multiple-myeloma?utm_source=sfmc&utm_medium=email&utm_campaign=02012023_OncLive_SAN-23-OSD1504_Global MM CC_Sanofi Sarclisa - Denmark&eKey=amFuYm9ydXAxOTc4QGdtYWlsLmNvbQ==

                    1 Reply Last reply
                    0
                    • B Offline
                      B Offline
                      bibob
                      wrote on sidst redigeret af
                      #46

                      Just a moment...

                      favicon

                      (www.onclive.com)

                      1 Reply Last reply
                      0
                      • B Offline
                        B Offline
                        bibob
                        wrote on sidst redigeret af
                        #47

                        https://www.onclive.com/view/chari-spotlights-efficacy-of-talquetamab-and-next-steps-for-exploration-in-r-r-multiple-myeloma?utm_source=sfmc&utm_medium=email&utm_campaign=%25%25emailname_%25%25&eKey=%25%25eKey%25%25&utm_source=sfmc&utm_medium=email&utm_campaign=02012023_OncLive_SAN-23-OSD1504_Global MM CC_Sanofi Sarclisa - Denmark&eKey=amFuYm9ydXAxOTc4QGdtYWlsLmNvbQ==

                        1 Reply Last reply
                        0
                        • B Offline
                          B Offline
                          bibob
                          wrote on sidst redigeret af
                          #48

                          Just a moment...

                          favicon

                          (www.onclive.com)

                          1 Reply Last reply
                          0
                          • BulderB Offline
                            BulderB Offline
                            Bulder
                            wrote on sidst redigeret af
                            #49

                            Tak bibob

                            1 Reply Last reply
                            0
                            • A Offline
                              A Offline
                              AaBforever
                              wrote on sidst redigeret af
                              #50

                              Bundvending...snart...
                              ?

                              1 Reply Last reply
                              0
                              • E Offline
                                E Offline
                                E_L
                                wrote on sidst redigeret af
                                #51

                                Novartis Ag (NVS) Q4 2022 Earnings Call Transcript https://www.fool.com/earnings/call-transcripts/2023/02/01/novartis-ag-nvs-q4-2022-earnings-call-transcript/ for Kesimpta

                                1 Reply Last reply
                                0
                                • E Offline
                                  E Offline
                                  E_L
                                  wrote on sidst redigeret af
                                  #52

                                  Understanding the Role of CD20-CD3 https://www.hmpgloballearningnetwork.com/site/onc/biological-pathways-reviews/cd20-cd3

                                  1 Reply Last reply
                                  0
                                  • E Offline
                                    E Offline
                                    E_L
                                    wrote on sidst redigeret af
                                    #53

                                    has anyone seen prognoses for Kesimpta sales for 2023? i underestimated this for '22, but even this strong year was mainly US so there should still be strong growth this year with Europe coming in

                                    1 Reply Last reply
                                    0
                                    • S Offline
                                      S Offline
                                      Sukkeralf
                                      wrote on sidst redigeret af
                                      #54

                                      Based on q4 sales its looks like at least 1,5 billion in 2023

                                      1 Reply Last reply
                                      0
                                      • E Offline
                                        E Offline
                                        E_L
                                        wrote on sidst redigeret af
                                        #55

                                        yes, and i guess we should add some growth in europe
                                        to that

                                        1 Reply Last reply
                                        0
                                        • SolsenS Offline
                                          SolsenS Offline
                                          Solsen
                                          wrote on sidst redigeret af
                                          #56

                                          Ocrevus p 29 https://assets.cwp.roche.com/f/126832/x/0ef4d462d9/irp230202-a.pdf with +1,5 bn CHF in Q4

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper